Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease by Pharmacists

McPherson R Frohlich J Fodor J Genest J . Canadian Cardiovascular Society position statement — recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913–27.

Yusuf S Hawken S Ôunpuu S , on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937–52.

Tsuyuki RT . CPJ as an agent of change (editorial). Can Pharm J 2007;140:10.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Dyslipidemia in adults with diabetes. Can J Diabetes 2006;30(3):230–40.

Pasternak RC Smith SC Bairey-Merz CN ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024–8.

Thompson PD Clarkson PM Rosenson RS . An assessment of statin safety by muscle experts. Am J Cardiol 2006;97[suppl]:69C–76C.

Marcoff L Thompson PD . The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231–7.

Cohen D.E. Anania FA Chalasani N . An assessment of statin safety by hepatologists. Am J Cardiol 2006;97[suppl]:77C–81C.

Russo MW Jacobson IM . How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004;71:58–62.

Lee M . Basic skills in interpreting laboratory medicine. 3rd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2004.

ASHP therapeutic position statement on the safe use of niacin in the management of dyslipidemias. Am J Health Syst Pharm 1997;54:2815–9.

Health Canada. Drugs and Health Products. Association of Ezetrol (ezetimibe) with myalgia, rhabdomyolysis, hepatitis, pancreatitis, and thrombocytopenia (advisory). February 1, 2005. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2005/ezetrol_hpc-cps_e.html (accessed Oct. 22, 2007).

Tsuyuki RT Bungard TJ . Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy 2001;21(5):576–82.

Jackevicius C Mamdani M Tu J . Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462–7.

Blackburn D Dobson R Blackburn J Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a cardiovascular event: a retrospective cohort study. Can J Cardiol 2005;21(6):485–8.

Ho PM Spertus JA Masoudi FA Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842–7.

Rasmussen JN Chong A Alter DA . Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297(2):177–86.

Wu JY Leung WY Chang S Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomized controlled trial. BMJ 2006;333:522.

Lee JK Grace KA Taylor AJ . Effect of a pharmacy care program on medication adherence and persistence, blood pressure and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563–71.